Subject of the present invention is a diluted anesthetic solution, to be used cold, comprising the association of two different local anesthetics, one with a short duration of action and the other with a long duration of action and optionally in association with one or more adjuvant drugs having antibiotic, antifibrinolytic or antitumor action. With this association it is possible to prolong up to 150 m′ duration of action in addition to offering better management of perioperative problems both as a request for analgesic drugs for post-operative pain, but also as a support to alleviate and reduce complications in some way connected to certain surgical procedures. The invention concerns also specific packaging with specific formulations, such as to make the immediate use of the mixture itself possible for different interventions.

Disclosed herein are compositions and methods useful for the treatment of pulmonary hypertension, such as pulmonary arterial hypertension (PAH), in a subject in need thereof. Also disclosed herein are compositions and methods useful for the treatment of cancers characterized by an increase in HIT-2 a expression and/or activity in a subject in need thereof. In some embodiments, the methods include administering a therapeutic composition comprising one or more of ethacridine, propantheline, etoposide, irinotecan, quinidine, and hydroxy ethylapoquimne (HEAQ), and/or an analog thereof.

Disclosed herein are compositions and methods useful for the treatment of pulmonary hypertension, such as pulmonary arterial hypertension (PAH), in a subject in need thereof. Also disclosed herein are compositions and methods useful for the treatment of cancers characterized by an increase in HIT-2 a expression and/or activity in a subject in need thereof. In some embodiments, the methods include administering a therapeutic composition comprising one or more of ethacridine, propantheline, etoposide, irinotecan, quinidine, and hydroxy ethylapoquimne (HEAQ), and/or an analog thereof.

The invention relates to a method for increasing the lifespan of animal sperm comprising contacting said sperm with an inhibitor of Slo3 potassium channel.

The invention also relates to a use of an inhibitor of Slo3 potassium channel, for increasing the lifespan of animal sperm or motility of capacitated animal sperm, comprising contacting an inhibitor of Slo3 potassium channel with said sperm. Moreover, the invention relates to an artificial insemination instrument for use in artificial insemination of an animal, comprising animal sperm in contact with an inhibitor of Slo3 potassium channel.

The invention also relates to a method for artificially inseminating an animal using said artificial insemination instrument.

Eventually, the invention relates to a method for increasing the fertility of an animal, comprising contacting sperm of said animal with an inhibitor of Slo3 potassium channel; then artificially inseminating said animal with said sperm.

The invention relates to a method for increasing the lifespan of animal sperm comprising contacting said sperm with an inhibitor of Slo3 potassium channel.

The invention also relates to a use of an inhibitor of Slo3 potassium channel, for increasing the lifespan of animal sperm or motility of capacitated animal sperm, comprising contacting an inhibitor of Slo3 potassium channel with said sperm. Moreover, the invention relates to an artificial insemination instrument for use in artificial insemination of an animal, comprising animal sperm in contact with an inhibitor of Slo3 potassium channel.

The invention also relates to a method for artificially inseminating an animal using said artificial insemination instrument.

Eventually, the invention relates to a method for increasing the fertility of an animal, comprising contacting sperm of said animal with an inhibitor of Slo3 potassium channel; then artificially inseminating said animal with said sperm.

A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (C.sub.max) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.

A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (C.sub.max) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.

A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (C.sub.max) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.

Disclosed herein is a dietary supplement containing alpha-glyceryl phosphoryl choline, phosphatidylserine, and an alkalizing agent, and its use in methods of maintaining or improving brain functions, such as mental focus, clarity, long-term memory, short-term memory, analytical reasoning, higher learning, mental processing, mental clarity, creativity, procrastination, willpower, reasoning, mood, retrieval/recall, learning gradient, and reaction time. The supplement can also be used in methods of treating or preventing cognitive dysfunction and dementia.

Disclosed herein is a dietary supplement containing alpha-glyceryl phosphoryl choline, phosphatidylserine, and an alkalizing agent, and its use in methods of maintaining or improving brain functions, such as mental focus, clarity, long-term memory, short-term memory, analytical reasoning, higher learning, mental processing, mental clarity, creativity, procrastination, willpower, reasoning, mood, retrieval/recall, learning gradient, and reaction time. The supplement can also be used in methods of treating or preventing cognitive dysfunction and dementia.